SGS, the world’s leading testing, inspection and certification company, is pleased to announce that it has acquired Keystone Bioanalytical, a specialized provider of bioanalytical testing services based in Philadelphia, Pennsylvania (United States). Established in 2001, Keystone Bioanalytical specializes in quantitative liquid chromatography-mass spectrometry (LC-MS/MS) method development, validation, and analysis, including integrated biomarker analysis, as well as drug metabolite profiling and identification. Its 10,000 square foot GLP-compliant facility delivers bioanalysis across both pre-clinical and clinical phases of the drug development lifecycle, encompassing pharmacokinetics and clinical trial studies.
Read the full article: SGS Acquires Keystone Bioanalytical, Strengthening End-to-End Drug Development Lifecycle Testing Capabilities for North American Pharma and Biotech Industries //
Source: https://www.prnewswire.com/news-releases/sgs-acquires-keystone-bioanalytical-strengthening-end-to-end-drug-development-lifecycle-testing-capabilities-for-north-american-pharma-and-biotech-industries-302761481.html